MOMA Therapeutics
Cambridge, MA, USA
About MOMA Therapeutics MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATICTM platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential, MOMA is rapidly advancing its pipeline toward responses in the clinic. MOMA's lead assets include: MOMA-313 - A selective polymerase helicase theta inhibitor in Phase 1 MOMA - 989 - A next generation selective PARP1 inhibitor currently in IND enabling studies MOMA-341 - A selective Werner helicase inhibitor entering Phase 1 in 2025 MOMA's pre-clinical pipeline consisting of wholly-owned assets and discovery partnerships with Roche and Bayer. For more...